Full Press Release Details
– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib –
– Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib –
– Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT –
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, have been accepted for a late-breaking oral presentation, and that a new biomarker analysis from the Phase 2 STRIDE trial of envudeucitinib has been accepted as an e-poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31, 2026, in Denver, Colorado.
Details regarding the presentations are as follows:
Late-Breaking Oral Presentation
Title: Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies
Location: Bellco Theatre 3
Date and Time: March 28, 2026, at 11:12 am MDT
E-Poster Presentations
Title: Envudeucitinib Attenuates Inflammatory Biomarkers in Plaque Psoriasis at Both a Proteomic and Transcriptomic Level: A Subgroup Analysis of Tape Strip Biomarkers from the STRIDE Phase 2 Clinical Trial
Poster number: 73714
The presentations will be made available under the Publications section of the Alumis website on March 28, 2026 in accordance with the AAD embargo policy.
Investor Conference Call and Webcast Details
Alumis will also host a webcast for the investment community on Sunday, March 29, 2026, at 5:00 pm MDT (7:00 pm EDT) to review the Phase 3 ONWARD data being presented at AAD. The live webcast can be accessed via this link or on the Events tab on the Investors section of the Company’s website. A replay of the webcast will be made available on the Company’s website following the call.
About Envudeucitinib
Envudeucitinib is a next‑generation, highly selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2) designed to correct immune dysregulation across a range of diseases driven by proinflammatory mediators, including IL-23, IL-17, and Type I interferon. Clinical data indicate its selective targeting delivered sustained, maximal 24-hour inhibition in patients with psoriasis while minimizing off-target binding and effects. Alumis is currently evaluating the long-term efficacy and safety of envudeucitinib in the Phase 3 ONWARD3 clinical program for moderate-to-severe plaque psoriasis. Envudeucitinib is also being evaluated in LUMUS, a potentially pivotal Phase 2b clinical trial in patients with systemic lupus erythematosus, with topline data expected in the third quarter of 2026.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alumis’ future plans and prospects including development and commercialization of its pipeline, Alumis’ expectations with respect to the timing of availability of topline data from its clinical trials, any expectations regarding the safety, efficacy or tolerability of envudeucitinib or A-005, the potential of envudeucitinib to treat moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and the potential of A-005 to treat neurodegenerative diseases. Any forward-looking statements in this press release are based on Alumis’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to Alumis’ ability to advance envudeucitinib and A-005 and to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing and results of preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, Alumis’ ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC), including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Tags
immune-mediated diseases